News

In a recent study of mothers of FNAIT-affected children, anxiety was the most common psychological symptom reported.

Nipocalimab’s success in gMG may bode well for its efficacy in treating FNAIT, a serious fetal condition with no approved therapies.

Nearly one in three babies born to mothers with Glanzmann’s thrombasthenia developed FNAIT in a recent study.

In the study, FNAIT was often associated with other conditions such as preeclampsia, neonatal sepsis and necrotizing enterocolitis.

Patients diagnosed with intracranial hemorrhage pre- and postnatally may have an elevated risk of neurological and behavioral impairment.

A recent case report describes a newborn with severe thrombocytopenia who was found to have a novel mutation in the MECOM gene.

Very premature infants exposed to preeclampsia needed more platelet transfusions even though FNAIT was not observed in the sample.

In a recent study, researchers identified the clinical signs that may point to a rare subtype of intracranial hemorrhage.

A group of obstetricians, pediatricians and other healthcare professionals reached a consensus on several aspects of FNAIT care.

Rallybio announced its clinical trial investigating the drug RLYB212, intended for the prevention of FNAIT, was discontinued.